hrcak mascot   Srce   HID

Stručni rad

Extensive clinical experience with clopidogrel in the treatment of acute coronary syndrome

Darja Milovanovič Jarh ; Krka, d. d., Novo mesto, Slovenia
Breda Barbič-Žagar   ORCID icon orcid.org/0000-0002-1173-7361 ; Krka, d. d., Novo mesto, Slovenia
Mateja Grošelj ; Krka, d. d., Novo mesto, Slovenia

Puni tekst: engleski, pdf (79 KB) str. 440-442 preuzimanja: 155* citiraj
APA 6th Edition
Milovanovič Jarh, D., Barbič-Žagar, B. i Grošelj, M. (2011). Extensive clinical experience with clopidogrel in the treatment of acute coronary syndrome. Cardiologia Croatica, 6 (12), 440-442. Preuzeto s https://hrcak.srce.hr/74636
MLA 8th Edition
Milovanovič Jarh, Darja, et al. "Extensive clinical experience with clopidogrel in the treatment of acute coronary syndrome." Cardiologia Croatica, vol. 6, br. 12, 2011, str. 440-442. https://hrcak.srce.hr/74636. Citirano 09.07.2020.
Chicago 17th Edition
Milovanovič Jarh, Darja, Breda Barbič-Žagar i Mateja Grošelj. "Extensive clinical experience with clopidogrel in the treatment of acute coronary syndrome." Cardiologia Croatica 6, br. 12 (2011): 440-442. https://hrcak.srce.hr/74636
Harvard
Milovanovič Jarh, D., Barbič-Žagar, B., i Grošelj, M. (2011). 'Extensive clinical experience with clopidogrel in the treatment of acute coronary syndrome', Cardiologia Croatica, 6(12), str. 440-442. Preuzeto s: https://hrcak.srce.hr/74636 (Datum pristupa: 09.07.2020.)
Vancouver
Milovanovič Jarh D, Barbič-Žagar B, Grošelj M. Extensive clinical experience with clopidogrel in the treatment of acute coronary syndrome. Cardiologia Croatica [Internet]. 2011 [pristupljeno 09.07.2020.];6(12):440-442. Dostupno na: https://hrcak.srce.hr/74636
IEEE
D. Milovanovič Jarh, B. Barbič-Žagar i M. Grošelj, "Extensive clinical experience with clopidogrel in the treatment of acute coronary syndrome", Cardiologia Croatica, vol.6, br. 12, str. 440-442, 2011. [Online]. Dostupno na: https://hrcak.srce.hr/74636. [Citirano: 09.07.2020.]
Puni tekst: hrvatski, pdf (79 KB) str. 440-442 preuzimanja: 159* citiraj
APA 6th Edition
Milovanovič Jarh, D., Barbič-Žagar, B. i Grošelj, M. (2011). Opsežno kliničko iskustvo primjene klopidogrela u liječenju akutnog koronarnog sindroma. Cardiologia Croatica, 6 (12), 440-442. Preuzeto s https://hrcak.srce.hr/74636
MLA 8th Edition
Milovanovič Jarh, Darja, et al. "Opsežno kliničko iskustvo primjene klopidogrela u liječenju akutnog koronarnog sindroma." Cardiologia Croatica, vol. 6, br. 12, 2011, str. 440-442. https://hrcak.srce.hr/74636. Citirano 09.07.2020.
Chicago 17th Edition
Milovanovič Jarh, Darja, Breda Barbič-Žagar i Mateja Grošelj. "Opsežno kliničko iskustvo primjene klopidogrela u liječenju akutnog koronarnog sindroma." Cardiologia Croatica 6, br. 12 (2011): 440-442. https://hrcak.srce.hr/74636
Harvard
Milovanovič Jarh, D., Barbič-Žagar, B., i Grošelj, M. (2011). 'Opsežno kliničko iskustvo primjene klopidogrela u liječenju akutnog koronarnog sindroma', Cardiologia Croatica, 6(12), str. 440-442. Preuzeto s: https://hrcak.srce.hr/74636 (Datum pristupa: 09.07.2020.)
Vancouver
Milovanovič Jarh D, Barbič-Žagar B, Grošelj M. Opsežno kliničko iskustvo primjene klopidogrela u liječenju akutnog koronarnog sindroma. Cardiologia Croatica [Internet]. 2011 [pristupljeno 09.07.2020.];6(12):440-442. Dostupno na: https://hrcak.srce.hr/74636
IEEE
D. Milovanovič Jarh, B. Barbič-Žagar i M. Grošelj, "Opsežno kliničko iskustvo primjene klopidogrela u liječenju akutnog koronarnog sindroma", Cardiologia Croatica, vol.6, br. 12, str. 440-442, 2011. [Online]. Dostupno na: https://hrcak.srce.hr/74636. [Citirano: 09.07.2020.]

Sažetak
Acute coronary syndrome (ACS) is a major problem for healthcare systems, as it is the cause of a large number of hospitalisations every year. Moreover, as ACS may be a life-threatening condition, timely decisions on pharmacological management as well as coronary revascularisation strategies are needed. Clopidogrel has a strong evidence base supporting its use as an effective and well tolerated antiplatelet agent for the secondary prevention of ischemic events in patients with various cardiovascular conditions, including those with ACS. An evidence base demonstrating the efficacy and safety of antiplatelet therapy has also been established for Zyllt® (Krka's clopidogrel) in many post-authorisation safety and efficacy studies. The studies yielded important results and an extensive data base, which is not available for any other generic clopidogrel. The high efficacy and good safety as well as the reasonable price of Krka’s clopidogrel could undoubtedly contribute to a better compliance with the treatment in more patients with ACS.

Ključne riječi
acute coronary syndrome; secondary prevention; clopidogrel

Hrčak ID: 74636

URI
https://hrcak.srce.hr/74636

[hrvatski]

Posjeta: 630 *